Dymon Asia Capital (Singapore) Pte. Ltd. Viking Therapeutics, Inc. Transaction History
Dymon Asia Capital (Singapore) Pte. Ltd.
- $378 Million
- Q3 2024
A detailed history of Dymon Asia Capital (Singapore) Pte. Ltd. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Dymon Asia Capital (Singapore) Pte. Ltd. holds 5,000 shares of VKTX stock, worth $211,250. This represents 0.08% of its overall portfolio holdings.
Number of Shares
5,000
Previous 8,000
37.5%
Holding current value
$211,250
Previous $424,000
25.47%
% of portfolio
0.08%
Previous 0.11%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
473Shares Held
65.6MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$430 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$255 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$197 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$89.4 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$79.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.24B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...